From: Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers
Clinical characteristics | HER2 | EGFR | ALK/ROS1 | KRAS | P value |
---|---|---|---|---|---|
N | 25 | 74 | 39 | 40 | |
Age, years (median,range) | 55(44–77) | 58(27–80) | 54(37–77) | 64.5(33–80) | 0.002 |
< 65 | 21(84.0%) | 55(74.3%) | 28(71.8%) | 20(50.0%) | |
≥ 65 | 4(16.0%) | 19(25.7%) | 11(28.2%) | 20(50.0%) | |
Gender | |||||
Male | 12(48.0%) | 37(50.0%) | 20(51.3%) | 33(82.5%) | 0.004 |
Female | 13(52.0%) | 37(50.0%) | 19(48.7%) | 7(17.5%) | |
Smoking status | |||||
Non-smoker | 18(72.0%) | 56(75.7%) | 29(74.4%) | 15(37.5%) | <0.001 |
Smoker | 7(28.0%) | 18(24.3%) | 10(25.6%) | 25(62.5%) | |
PS | |||||
0–1 | 22(88.0%) | 68(91.9%) | 36(92.3%) | 32(80.0%) | 0.269 |
≥ 2 | 3(12.0%) | 6(8.1%) | 3(7.7%%) | 8(20.0%) | |
Therapy | |||||
Monotherapy | 4(16.0%) | 9(12.2%) | 3(7.7%) | 9(22.5%) | 0.570 |
Plus carboplatin | 14(56.0%) | 42(56.8%) | 24(61.5%) | 23(57.5%) | |
Plus cisplatin | 7(28.0%) | 23(31.1%) | 12(30.8%) | 8(20.0%) | |
Maintenance therapy | 7(28.0%) | 18(24.3%) | 13(33.3%) | 5(12.5%) | 0.175 |
No maintenance | 18(72.0%) | 56(75.7%) | 26(66.7%) | 35(87.5%) |